<DOC>
	<DOCNO>NCT02457559</DOCNO>
	<brief_summary>This study determine long-term safety , tolerability , efficacy tirabrutinib adult prior tirabrutinib study whose disease progress parent study . The dose regimen base prior dose regimen parent study .</brief_summary>
	<brief_title>Long-term Safety Efficacy Tirabrutinib Adults With Relapsed/Refractory B-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Key Currently enrol prior tirabrutinib study Did discontinue treatment tirabrutinib reason enroll study Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 enrollment study Any Grade 3 4 nonhematologic toxicity investigator considers relate previous tirabrutinib use must resolve , revert Grade 1 , revert baseline prior study prior Day 1 study Negative serum urine pregnancy test require female individual ( unless surgically sterile great 2 year post menopausal ) Male female individual childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception describe protocol . Lactating female must agree discontinue nursing study drug administer Ability agreement attend protocolspecified visit study site Able comprehend willing sign inform consent form Key Known hypersensitivity tirabrutinib , metabolite , formulation excipients Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>